Arterial embolization hyperthermia using as2O3 nanoparticles in VX2 carcinoma-induced liver tumors

PLoS ONE

Volumn 6, Issue 3, 2011, Pages

  Yu, Hui ^a   Zhu, Guang Yu ^a   Xu, Rui Zhi ^b   Niu, Huan Zhang ^a   Lu, Qin ^a   Li, Guo Zhao ^a   Wang, Zi Yu ^a   Zhang, Dong Sheng ^a   Gu, Ning ^b   Teng, Gao Jun ^a  

^a MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

^b Southeast University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ARSENIC TRIOXIDE; ASPARTATE AMINOTRANSFERASE; IODINATED POPPYSEED OIL; NANOPARTICLE; SODIUM CHLORIDE; VASCULOTROPIN; CD31 ANTIGEN; ORGANOARSENIC DERIVATIVE; OXIDE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER SURVIVAL; CHEMOEMBOLIZATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEASIBILITY STUDY; HISTOPATHOLOGY; HUMAN; HYPERTHERMIA; LIVER FUNCTION TEST; LIVER TOXICITY; LIVER TUMOR; MALE; MICROVASCULATURE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SOLID TUMOR; SURVIVAL TIME; TRANSMISSION ELECTRON MICROSCOPY; TUMOR GROWTH; TUMOR NECROSIS; TUMOR VOLUME; ANGIOGRAPHY; ANIMAL; ARTIFICIAL EMBOLISM; BLOOD; HYPERTHERMIC THERAPY; IMMUNOHISTOCHEMISTRY; LIVER; METABOLISM; METHODOLOGY; NECROSIS; PATHOLOGY; PATHOPHYSIOLOGY; RABBIT; RADIOGRAPHY; SURVIVAL; TEMPERATURE; TREATMENT OUTCOME; ULTRASTRUCTURE; VASCULARIZATION;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

ANGIOGRAPHY; ANIMALS; ANTIGENS, CD31; ARSENICALS; EMBOLIZATION, THERAPEUTIC; HYPERTHERMIA, INDUCED; IMMUNOHISTOCHEMISTRY; LIVER; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MALE; MICROVESSELS; NANOPARTICLES; NECROSIS; OXIDES; RABBITS; SURVIVAL ANALYSIS; TEMPERATURE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79952958380     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0017926     Document Type: Article

References (50)

1. He J, Gu D, Wu X, Reynolds K, Duan X, et al. (2005) Major causes of death among men and women in China. N Engl J Med 353: 1124-1134.
2. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, et al. (2008) Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100: 698-711.
3. Parkin DM, Bray F, Ferlay J, Pisani P, (2005) Global cancer statistics, 2002. Ca-a Cancer Journal for Clinicians 55: 74-108.
4. Moroz P, Jones SK, Gray BN, (2002) Magnetically mediated hyperthermia: current status and future directions. Int J Hyperthermia 18: 267-284.
5. Pacella CM, Bizzarri G, Cecconi P, Caspani B, Magnolfi F, et al. (2001) Hepatocellular carcinoma: Long-term results of combined treatment with laser thermal ablation and transcatheter arterial chemoembolization. Radiology 219: 669-678.
6. Vogl TJ, Mack MG, Balzer JO, Engelmann K, Straub R, et al. (2003) Liver metastases: Neoadjuvant downsizing with transarterial chemoembolization before laser-induced thermotherapy. Radiology 229: 457-464.
7. Llovet JM, Real MI, Montana X, Planas R, Coll S, et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359: 1734-1739.
8. Moroz P, Jones SK, Gray BN, (2002) The effect of tumour size on ferromagnetic embolization hyperthermia in a rabbit liver tumour model. Int J Hyperthermia 18: 129-140.
9. Moroz P, Jones SK, Winter J, Gray BN, (2001) Targeting liver tumors with hyperthermia: ferromagnetic embolization in a rabbit liver tumor model. J Surg Oncol 78: 22-29; discussion 30-21.
10. Jones SK, Winter JG, Gray BN, (2002) Treatment of experimental rabbit liver tumours by selectively targeted hyperthermia. Int J Hyperthermia 18: 117-128.
11. Gallagher RE, (1998) Arsenic-new life for an old potion. N Engl J Med 339: 1389-1391.
12. Kito M, Akao Y, Ohishi N, Yagi K, Nozawa Y, (2002) Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 291: 861-867.
13. Liu B, Pan S, Dong X, Qiao H, Jiang H, et al. (2006) Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice. Cancer Sci 97: 675-681.
14. Xu HY, Yang YL, Gao YY, Wu QL, Gao GQ, (2000) Effect of arsenic trioxide on human hepatoma cell line BEL-7402 cultured in vitro. World J Gastroenterol 6: 681-687.
15. Hyun Park W, Hee Cho Y, Won Jung C, Oh Park J, Kim K, et al. (2003) Arsenic trioxide inhibits the growth of A498 renal cell carcinoma cells via cell cycle arrest or apoptosis. Biochem Biophys Res Commun 300: 230-235.
16. Maeda H, Hori S, Nishitoh H, Ichijo H, Ogawa O, et al. (2001) Tumor growth inhibition by arsenic trioxide (As2O3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61: 5432-5440.
17. Roboz GJ, Dias S, Lam G, Lane WJ, Soignet SL, et al. (2000) Arsenic trioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 96: 1525-1530.
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
19. Llovet JM, Bruix J, (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 37: 429-442.
20. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, et al. (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30: 6-25.
21. Biolato M, Marrone G, Racco S, Di Stasi C, Miele L, et al. (2010) Transarterial chemoembolization (TACE) for unresectable HCC: a new life begins? Eur Rev Med Pharmacol Sci 14: 356-362.
22. Johannsen M, Gneveckow U, Eckelt L, Feussner A, Waldofner N, et al. (2005) Clinical hyperthermia of prostate cancer using magnetic nanoparticles: presentation of a new interstitial technique. Int J Hyperthermia 21: 637-647.
23. Vogl TJ, Straub R, Eichler K, Sollner O, Mack MG, (2004) Colorectal carcinoma metastases in liver: laser-induced interstitial thermotherapy-local tumor control rate and survival data. Radiology 230: 450-458.
24. Griffin RJ, Lee SH, Rood KL, Stewart MJ, Lyons JC, et al. (2000) Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia 2: 555-560.
25. Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, et al. (2003) Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia 19: 575-589.
26. Zhu AL, Liu LX, Piao DX, Lin YX, Zhao JP, et al. (2004) Liver regional continuous chemotherapy: use of femoral or subclavian artery for percutaneous implantation of catheter-port systems. World J Gastroenterol 10: 1659-1662.
27. Moroz P, Pardoe H, Jones SK, St Pierre TG, Song S, et al. (2002) Arterial embolization hyperthermia: hepatic iron particle distribution and its potential determination by magnetic resonance imaging. Phys Med Biol 47: 1591-1602.
28. Ruizhi X, Hui Y, Yu Z, Ming M, Zhongping C, et al. (2009) Three-Dimensional Model for Determining Inhomogeneous Thermal Dosage in a Liver Tumor During Arterial Embolization Hyperthermia Incorporating Magnetic Nanoparticles. Magnetics, IEEE Transactions on 45: 3085-3091.
29. Ruizhi X, Yu Z, Ming M, Jingguang X, Jiwei L, et al. (2007) Measurement of Specific Absorption Rate and Thermal Simulation for Arterial Embolization Hyperthermia in the Maghemite-Gelled Model. Magnetics, IEEE Transactions on 43: 1078-1085.
30. Hamaguchi S, Tohnai I, Ito A, Mitsudo K, Shigetomi T, et al. (2003) Selective hyperthermia using magnetoliposomes to target cervical lymph node metastasis in a rabbit tongue tumor model. Cancer Sci 94: 834-839.
31. Wang ZY, Song J, Zhang DS, (2009) Nanosized As2O3/Fe2O3 complexes combined with magnetic fluid hyperthermia selectively target liver cancer cells. World J Gastroenterol 15: 2995-3002.
32. Park MJ, Park IC, Bae IJ, Seo KM, Lee SH, et al. (2003) Tetraarsenic oxide, a novel orally administrable angiogenesis inhibitor. Int J Oncol 22: 1271-1276.
33. Patterson J, Strang R, (1979) The role of blood flow in hyperthermia. Int J Radiat Oncol Biol Phys 5: 235-241.
34. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH, (1999) Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 59: 6033-6037.
35. Lew YS, Kolozsvary A, Brown SL, Kim JH, (2002) Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res 62: 4202-4205.
36. Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, et al. (2000) Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia 14: 431-438.
37. Monzen H, Griffin RJ, Williams BW, Amano M, Ando S, et al. (2004) Study of arsenic trioxide-induced vascular shutdown and enhancement with radiation in solid tumor. Radiat Med 22: 205-211.
38. Hines-Peralta A, Sukhatme V, Regan M, Signoretti S, Liu ZJ, et al. (2006) Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. Radiology 240: 82-89.
39. Kito M, Matsumoto K, Wada N, Sera K, Futatsugawa S, et al. (2003) Antitumor effect of arsenic trioxide in murine xenograft model. Cancer Sci 94: 1010-1014.
40. Xu HY, Yang YL, Liu SM, Bi L, Chen SX, (2004) Effect of arsenic trioxide on human hepatocarcinoma in nude mice. World J Gastroenterol 10: 3677-3679.
41. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, et al. (2007) Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs 25: 77-84.
42. Lu Q, Teng GJ, Zhang Y, Niu HZ, Zhu GY, et al. (2008) Enhancement of p53 gene transfer efficiency in hepatic tumor mediated by transferrin receptor through trans-arterial delivery. Cancer Biol Ther 7: 218-224.
43. Yoon CJ, Chung JW, Park JH, Yoon YH, Lee JW, et al. (2003) Transcatheter arterial chemoembolization with paclitaxel-lipiodol solution in rabbit VX2 liver tumor. Radiology 229: 126-131.
44. Yan S, Zhang D, Gu N, Zheng J, Ding A, et al. (2005) Therapeutic effect of Fe2O3 nanoparticles combined with magnetic fluid hyperthermia on cultured liver cancer cells and xenograft liver cancers. J Nanosci Nanotechnol 5: 1185-1192.
45. Hajitou A, Lev DC, Hannay JA, Korchin B, Staquicini FI, et al. (2008) A preclinical model for predicting drug response in soft-tissue sarcoma with targeted AAVP molecular imaging. Proc Natl Acad Sci U S A 105: 4471-4476.
46. Paoloni MC, Tandle A, Mazcko C, Hanna E, Kachala S, et al. (2009) Launching a novel preclinical infrastructure: comparative oncology trials consortium directed therapeutic targeting of TNFalpha to cancer vasculature. PLoS One 4: e4972.
47. Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Noguchi R, et al. (2002) Synergistic effect of basic fibroblast growth factor and vascular endothelial growth factor in murine hepatocellular carcinoma. Hepatology 35: 834-842.
48. Hassouneh B, Islam M, Nagel T, Pan Q, Merajver SD, et al. (2007) Tetrathiomolybdate promotes tumor necrosis and prevents distant metastases by suppressing angiogenesis in head and neck cancer. Mol Cancer Ther 6: 1039-1045.
49. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M, et al. (1998) Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28: 68-77.
50. Weidner N, Semple JP, Welch WR, Folkman J, (1991) Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 324: 1-8.